Gallery
Company Bio
AMLo Biosciences is translating ground-breaking research in cancer biomarkers into a revolutionary range of prognostic and companion diagnostic products to improve patient outcomes and reduce the financial burden of cancers on global healthcare economies.
Its new prognostic tests will better identify a patient’s true risk of disease progression, so that individuals can be counselled and treated appropriately and precious healthcare resources can be targeted effectively to the patients who need it most.
AMLo Biosciences is currently working on prognostic products for three cancers where clinicians have a significant need for better information to enable them to manage and treat patients more effectively.
